Analyst Research Report Snapshot

Title:

Galectin Therapeutics, Inc. (GALT) - Financial Analysis Review

Price:

$125.00

Provider:

GlobalData

Date:

10 Feb 2014

Pages:

26

Type:

AcrobatPDF

Companies referenced:

GALT.OQ

Available for Immediate Download
Summary:

Galectin Therapeutics, Inc. (GALT) - Financial Analysis Review Summary Galectin Therapeutics, Inc. (Galectin Therapeutics) is a pharmaceutical company. The company discovers, develops and commercializes therapies for fibrotic disease and cancer. Galectin Therapeutics‘s producfts include GR-MD-02 and GM-CT-01. Its GR-MD-02 is a drug candidate used in the treatment of fibrotic liver disease associated with NASH; and GM-CT-01 is a vaccine used to treat patients with advanced melanoma, a deadly skin cancer. GlobalData's Galectin Therapeutics, Inc. (GALT) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years. Galectin Therapeutics, Inc. Key Recent Developments: Jan 27, 2014: Galectin Therapeutics and SBH Sciences Announce the Formation of Galectin Sciences, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration Jan 10, 2014: Galectin Therapeutics Announces Update on Financing Activities and Cash of $32.3 Million Dec 19, 2013: Published Preclinical Study Demonstrates Therapeutic Effect of Galectin Inhibitors in Fatty Liver Disease With Fibrosis Aug 14, 2013: Galectin Therapeutics Reports Second Quarter 2013 Financial Results May 10, 2013: Galectin Therapeutics Reports Q1 2013 Results This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better. Scope - Business description - A detailed description of the company's operations and business divisions. - Company history - Progression of key events associated with the company. - Major products and services - A list of major products, services and brands of the company. - Key competitors - A list of key competitors to the company. - Key employees - A list of the key executives of the company. - Executive biographies - A brief summary of the executives' employment history. - Key operational heads - A list of personnel heading key departments/functions. - Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details. - Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history. - Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history. Note: Some sections may be missing if data is unavailable for the company. Reasons to Buy - Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs. - Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services. - Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns,...

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.